A Phase I/II Clinical Trial to Evaluate the Safety and Efficacy of Nivolumab at the Fixed Dose 40 mg (Nivo40) in Patients With Relapsed or Refractory Hodgkins Lymphoma.
Phase of Trial: Phase I/II
Latest Information Update: 21 Nov 2017
At a glance
- Drugs Nivolumab (Primary)
- Indications Hodgkin's disease
- Focus Therapeutic Use
- 21 Nov 2017 New trial record